Article Text

PDF
FRI0296 WHI-131, JAK3 Inhibitor, Inhibits Osteoclastogenesis and Promotes Osteoblastogenesis
  1. Y.-H. Cheon1,
  2. J.-Y. Kim1,
  3. J.-M. Oh1,
  4. W.-S. Lee2,
  5. W.-H. Yoo2,
  6. M.-S. Lee3,
  7. C.-H. Lee3
  1. 1Anatomy, Wonkwang University, Iksan
  2. 2Internal Medicine, Chonbuk National University Medical School, Jeonju
  3. 3Internal Medicine, Wonkwang University Hospital, Iksan, Korea, Republic Of

Abstract

Background WHI-131/JANEX-1 (4-(4'Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline), quinazoline-type small molecule compound is well known a JAK3 inhibitor that demonstrated as potent therapeutic agent about anti-inflammatory, anti-cancer, and anti-leukemia in several animal models. However, has not been fully investigated for regulatory effects on osteoblast and osteoclast activity by WHI-131.

Objectives Therefore, in this study, we examined the effects of WHI-131 in bone remodeling during osteoblast and osteoclast differentiation.

Results WHI-131 decreased RANKL-induced osteoclast differentiation on the bone marrow derived macrophages cultures and reduced the resorbing activity of mature osteoclasts. WHI-131 suppressed the protein and mRNA expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and down-regulated mRNA expression levels of TRAP, osteoclast-associated receptor (OSCAR), dendritic cell-specific transmembrane protein (DC-STAMP), osteoclast stimulatory transmembrane protein (OC-STAMP), d2 isoform of vacuolar H+ ATPase V(0) domain (ATP6v0d2), and Cathepsin K. WHI-131 diminished the phosphorylation of Akt and degradation of I-kB. In addition, WHI-131 suppressed Ca2+ oscillation by inhibiting phosphorylation of the c-Src-Btk-PLCg2 pathway. WHI-131 expression appeared to increase based on alkaline phosphate and alizarin red staining in relation to increased activity of the differentiation of primary osteoblast cells. WHI-131 increased the mRNA expression of genes related to osteoblast differentiation, including runt-related transcription factor 2 (Runx2), ALP, collagen type 1a (Col1a), osteocalcin (OCN), and OPN and induced the phosphorylation of Akt, p38, and Smad 1/5/8. Interestingly, WHI-131 had a notable anti-resorbing effects in the LPS-induced calvaria bone loss model in vivo. WHI-131 plays a dual role by inhibiting osteoclast differentiation and promoting osteoblast differentiation.

Conclusions Thus, WHI-131 may be a useful pharmacological agent that acts as a safe and effective dual-action therapeutic against osteoporosis, promoting robust bone growth while inhibiting resorption.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.